Intestinal Ultrasound Scan in Acute Severe Ulcerative Colitis in children: a multicenter prospective study on behalf of the Porto IBD Working Group of ESPGHAN

Inflammatory Bowel Disease

Histological activity predicts relapse in pediatric ulcerative colitis despite mucosal healing: a multicenter study from the pediatric IBD Porto group of ESPGHAN

J Crohns Colitis

Trivić Mažuranić I, Aloi M, Bramuzzo M, Chiantese C, D'Arcangelo G, Gattenlöhner S, Gianolio L, Granot M, Hızarcıoğlu Gülşen H, Hussey S, Kang B, Kolho KL, de Laffolie J, Lega S, Martinelli M, Matar M, Mayer C, Miele E, Norsa L, Panarese I, Rinawi F, Rohani P, Romano C, Sansotta N, Scarallo L, Shouval DS, Staiano A, Strisciuglio C, Tomas D, Yerushalmy-Feler A, Zojaji R, Hojsak I

doi: 10.1093/ecco-jcc/jjag074

Further Publications

Disorders of Gut-Brain Interaction like symptoms in Children with Inflammatory Bowel Disease: A Multicenter Prospective Study from the Pediatric IBD Porto Group of the ESPGHAN

Am J Gastroenterol

Martinelli M, Salomone S, Strisciuglio C, Zellos A, Romano C, Dipasquale V, Bramuzzo M, Lega S, Aloi M, D'Arcangelo G, Rodríguez-Belvís MV, Colucci A, Miele E, Staiano A, Eleftheria R

doi: 10.14309/ajg.0000000000004140

Inflammatory Bowel Disease

Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-week Multicenter Study from the Porto Group of ESPGHAN

Clin Gastroenterol Hepatol

Yerushalmy-Feler A, Spencer EA, Dubinsky MC, Suskind DL, Mitrova K, Hradsky O, Conrad MA, Kelsen JR, Sladek M, Yeh PJ, Tzivinikos C, Henderson P, Wlazlo M, Hackl L, Shouval DS, Mouratidou N, Bramuzzo M, Urlep D, Olbjørn C, Mancuso G, Schneider AM, Pujol-Muncunill G, Yogev D, Kang B, Gasparetto M, Rungø C, Romano C, Martinelli M, Kolho KL, Hojsak I, Norsa L, Rinawi F, Sansotta N, Rimon RM, Granot M, Scarallo L, Trindade E, Rodríguez-Belvís MV, Turner D, Cohen S

doi: 10.1016/j.cgh.2026.02.012

Inflammatory Bowel Disease

Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study

Inflamm Bowel Dis

Ünal NG, Bakkaloğlu OK, Kav T, Eşkazan T, Kani HT, Akpınar A, Akıncıoğlu P, Dağcı G, Şendur İ, Büyüktorun İ, Barutçu S, Kılıç G, Bengi G, Çavuş B, Oruç N, Alahdab YÖ, Atuğ Ö, Dinçer D, Karakan T, Hatemi Aİ, Erzin YZ, Tezel A, Törüner M, Akyüz F, Çelik AF

doi: 10.1093/ibd/izag126

Inflammatory Bowel Disease

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Inflamm Bowel Dis

Turner D, Lomax KG, Veereman G, Griffiths AM, Kierkuś J, Kang B, Berezny K, Padgett L, Mao G, Zitser Y, Strauss RS, Verhoeven J, Adedokun OJ, Hyams JS

doi: 10.1093/ibd/izaf322

Inflammatory Bowel Disease

Characterization of remission levels in patients with ulcerative colitis treated with 5-aminosalicylates: results of the cross-sectional CARUC-ASA study by the Belgian IBD Research and Development Group

J Crohns Colitis

Reenaers C, Lambrecht G, Pouillon L, Baert F, Cremer A, Colard A, Claessens C, Billiet T, Geldof J, De Zutter A, Rahier JF, Somers M, Reynders D, Vansteenkiste L, Arijs I, Louis E, Belgian IBD Research and Development Group (BIRD), Verstockt B

doi: 10.1093/ecco-jcc/jjag100

Inflammatory Bowel Disease

Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study

J Crohns Colitis

D'Amico F, Fanizzi F, Dal Buono A, Gabbiadini R, Nardone OM, Zilli A, Allocca M, Lauriola GM, Jairath V, Peyrin-Biroulet L, Fiorino G, Castiglione F, Massimino L, Mastronardi M, Armuzzi A, Danese S

doi: 10.1093/ecco-jcc/jjag062

RECOMMENDED

Inflammatory Bowel Disease

Early transmural response assessed by intestinal ultrasound predicts long-term clinical remission in patients with IBD: Results from the TRUST BEYOND study

★ 3 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

Inflamm Bowel Dis

Kucharzik T, Helwig U, Seibold F, Biedermann L, Högenauer C, Fischer I, Hammer L, Rath S, Maaser C

doi: 10.1093/ibd/izag074

Inflammatory Bowel Disease

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Lancet Gastroenterol Hepatol

Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group

doi: 10.1016/S2468-1253(25)00198-0

Related content

Histological activity predicts relapse in pediatric ulcerative colitis despite mucosal healing: a multicenter study from the pediatric IBD Porto group of ESPGHAN

Disorders of Gut-Brain Interaction like symptoms in Children with Inflammatory Bowel Disease: A Multicenter Prospective Study from the Pediatric IBD Porto Group of the ESPGHAN

Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-week Multicenter Study from the Porto Group of ESPGHAN

Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Characterization of remission levels in patients with ulcerative colitis treated with 5-aminosalicylates: results of the cross-sectional CARUC-ASA study by the Belgian IBD Research and Development Group

Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study

Early transmural response assessed by intestinal ultrasound predicts long-term clinical remission in patients with IBD: Results from the TRUST BEYOND study

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study